Helios: We are committed to your health
Helios is Europe's leading private healthcare provider, with approximately 126,000 employees. Together with Quirónsalud in Spain and Latin America and the Eugin Group with a global network of reproductive clinics, Helios Group in Germany is part of the holding Helios Health. Every year more than 24 million patients choose Helios for medical treatment. In 2022, the company’s sales totaled €11.7 billion.
Helios Germany operates 87 acute care hospitals, about 240 outpatient care centers with 600 accredited doctor's licenses, six prevention centers and 21 occupational medicine centers. Helios treats approximately 5.5 million patients annually, of whom 4.4 million are outpatients. With more than 76,000 employees, Helios generated sales of €7.0 billion in 2022. Helios is a partner in the "Wir für Gesundheit" hospital network. Helios Germany is headquartered in Berlin.
Quirónsalud operates 58 hospitals, including eight in Latin America, 100 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 18,9 million patients annually, of whom 17.8 million are outpatients. Quirónsalud has more than 47,000 employees and generated sales of €4.4 billion in 2022.
Eugin Group’s network comprises 44 clinics and additional 37 sites across ten countries on three continents. With about 1,800 employees, the company offers a wide spectrum of state-of-the-art services in the field of fertility treatments and generated sales of €250 million in 2022.
Fresenius Helios is committed to the highest quality clinical and nursing care. In addition to providing first-class medical care, Helios and Quirónsalud make important contributions to the advancement of medicine. This benefits patients, who can rely on Fresenius Helios hospitals for superior, state-of-the-art treatment and diagnostic procedures.
Helios Health is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.
Key figures (IFRS)
|€ in millions||2022||2021||Growth|
|11,716||10,891||+ 7 %|
|1,185||1,127||+ 5 %|
|10.1 %||10.3 %|
|642||1,021||- 37 %|
R & D expenses
Employees (December 31)
|125,700||123,484||+ 2 %|
Some figures adjusted for special items
Net income = Net income attributable to shareholders of Fresenius Helios